AR061399A1 - Derivados de tiotriazolilo - Google Patents

Derivados de tiotriazolilo

Info

Publication number
AR061399A1
AR061399A1 ARP060104506A ARP060104506A AR061399A1 AR 061399 A1 AR061399 A1 AR 061399A1 AR P060104506 A ARP060104506 A AR P060104506A AR P060104506 A ARP060104506 A AR P060104506A AR 061399 A1 AR061399 A1 AR 061399A1
Authority
AR
Argentina
Prior art keywords
aryl
alkyl
alicyclic
heteroalicyclic
alkoxy
Prior art date
Application number
ARP060104506A
Other languages
English (en)
Inventor
Pradyumna Mohanty
Silvia Noiman
Prasad Ramakrishna
Oren M Becker
Yael Marantz
Ashis Saha
Sharon Shacham
Nili Schutz
Dongli Chen
Merav Fichman
A Reddy
Chris Penland
Original Assignee
Epix Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epix Pharm Inc filed Critical Epix Pharm Inc
Publication of AR061399A1 publication Critical patent/AR061399A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Antagonistas de los canales ionicos Kv 1.5,compuestos derivados de tiotriazolilo representados por la formula 1, y síntesis y usos de los mismos para tratar enfermedades mediadas directa o indirectamente por los canales ionicos Kv 1.5. Dichas enfermedades incluyen numerosos trastornos cardiacos entre los que se incluyen la fibrilacion atrial y otras enfermedades, así como epilepsia, ansiedad, depresion, pérdida de la memoria relacionada con la edad, migrana obesidad, mal de Parkinson o enfermedad de Alzheimer. Métodos de preparacion y nuevos intermediarios y sus sales farmacéuticas. Reivindicacion 1: Un compuesto, caracterizado porque tiene la formula (1) en donde R1 se selecciona del grupo formado por alquilo C1-7 de cadena lineal o ramificada; y grupos alicíclico C3-10, heteroalicíclico, arilo o heteroarilo, en donde dichos grupos alicíclico, heteroalicíclico, arilo o heteroarilo están sustituidos opcionalmente con uno o más entre un grupo halogeno; alquilo C1-6; alcoxi C1-6; ciano, hidroxialquilo C1-6; amino, alquilamino inferior o dialquilamino inferior; sulfonamida; o hidroxilo; y R1 está unido opcionalmente a través de un ligador alquilo C1-2 en lugar de un enlace directo; R2 puede ser un anillo alicíclico C3-10, heteroalicíclico, arilo, heteroarilo o arilo/(alicíclico o heterocíclico) fusionado sustituido opcionalmente con uno o más entre un halogeno, un grupo alquilo C1-3, alcoxi C1-6, ciano, hidroxialquilo C1-6; amino, alquilamino inferior o dialquilamino inferior; sulfonamida o hidroxilo; y R2 está unido opcionalmente a través de un ligador de alquilo C1-2 en lugar de un enlace directo; R3, R4 y R6 son, en forma independiente, H o alquilo inferior; R5 se selecciona del grupo formado por grupos alicíclico C3-10, heteroalicíclico, arilo o heteroarilo, en donde dichos grupos alicíclico, heteroalicíclico, arilo o heteroarilo están sustituidos opcionalmente de forma independiente con uno o más entre un halogeno, grupos de alquilo C1-6, alcoxi C1-6, ciano, arilo C1-6 alcoxi, amino, hidroxi o sulfonamida; y R5 está unido opcionalmente a través de un ligador de alquilo C1-2 en lugar de un enlace directo; en donde en ausencia de un enlace de puntos lineal, la línea de puntos circular representa un puente alquileno C1-3; o una sal aceptable para uso farmacéutico del mismo.
ARP060104506A 2005-10-13 2006-10-13 Derivados de tiotriazolilo AR061399A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72643605P 2005-10-13 2005-10-13

Publications (1)

Publication Number Publication Date
AR061399A1 true AR061399A1 (es) 2008-08-27

Family

ID=37963094

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060104506A AR061399A1 (es) 2005-10-13 2006-10-13 Derivados de tiotriazolilo

Country Status (2)

Country Link
AR (1) AR061399A1 (es)
WO (1) WO2007047394A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7786139B2 (en) 2006-11-21 2010-08-31 Omeros Corporation PDE10 inhibitors and related compositions and methods
WO2009143178A2 (en) * 2008-05-20 2009-11-26 Omeros Corporation Pde10 inhibitors and related compositions and methods
WO2017091513A1 (en) * 2015-11-24 2017-06-01 Daiichi Sankyo Company, Limited Novel azole derivatives as apelin receptor agonist
WO2024063740A2 (en) * 2022-09-20 2024-03-28 Istanbul Universitesi Rektorlugu Triazole and hydrazide-hydrazone derivative hybrid molecules with antitumoral effect and the synthesis methods of these molecules
US11932610B1 (en) 2023-10-17 2024-03-19 King Faisal University 4-(5-(3-fluorophenyl)-4-phenyl-4H-1,2,4-triazol-3-ylthio)butanoic acid as an antimicrobial compound
US11932612B1 (en) 2023-10-17 2024-03-19 King Faisal University 6-(5-(3-fluorophenyl)-4-phenyl-4H-1,2,4-triazol-3-ylthio)hexanoic acid as an antimicrobial compound

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0400725A2 (hu) * 2000-12-26 2004-07-28 Ranbaxy Laboratories Limited Szubsztituált 1,2,4-tiazol-3(2H,4H)-tion-származékok, eljárás előállításukra és az ezeket tartalmazó gyógyászati készítmények

Also Published As

Publication number Publication date
WO2007047394A3 (en) 2009-04-23
WO2007047394A2 (en) 2007-04-26

Similar Documents

Publication Publication Date Title
AR076460A1 (es) Antagonistas del receptor cxcr3
AR057131A1 (es) Derivados de purina como inmunomodulador
AR054799A1 (es) Derivados de oxindol
AR052902A1 (es) Derivados de piridazina, composicion farmaceutica que los contiene y su uso como agentes terapeuticos para enfermedades mediadas por la estearoil-coa desaturasa
CY1111469T1 (el) ΧΡΗΣΗ ΠΑΡΑΓΩΓΩΝ 3-ΦΑΙΝΥΛΘΕΙΟ-1Η-ΙΝΔΟΛΗ-1-ΟΞΙΚΟΥ ΟΞΕΟΣ ΩΣ ΡΥΘΜΙΣΤΕΣ ΤΗΣ ΔΡΑΣΗΣ ΤΟΥ ΥΠΟΔΟΧΕΑ CRTh2
CR8468A (es) Derivado de n-(1,5-difenil-1h-pirazol-3-il)metil)sulfonamida con afinidad por los receptores cb1
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
AR061399A1 (es) Derivados de tiotriazolilo
NO20045589L (no) Nye forbindelser
AR078045A1 (es) Derivados de pirimidina, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer
AR078408A1 (es) Derivados de indol como moduladores de los crac
CY1110977T1 (el) Υποκατεστημενα παραγωγα ινδολης για φαρμακευτικη συνθεση για θεραπεια ασθενειων του αναπνευστικου
AR077935A1 (es) Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina
EA200870127A1 (ru) Полициклические производные аминокислот и способы их применения
AR059016A4 (es) Derivados de aril-isoxazol-4-il-imidazo[1,2-a]piridina, metodo de preparacion, medicamentos que los contienen y usos en el tratamiento de trastornos cognitivos.
AR073574A1 (es) Inhibidores heterociclicos de los receptores de histamina para el tratamiento de una enfermedad
PE20070115A1 (es) Derivados de [1,3,5]-triazina como inhibidores de aspartil proteasas
EA200500342A1 (ru) Гетероциклические замещённые пиперазины для лечения шизофрении
PE20061096A1 (es) Derivados de oxiindol como agonistas 5-ht4
CY1108908T1 (el) Ενωσεις κινολινονης - καρβοξαμιδης ως αγωνιστες υποδοχεων 5-ητ4
CY1111733T1 (el) Παραγωγα 2-(1η-ινδολυλοσουλφανυλ)-βενζυλαμινης ως ssri
DE602006006850D1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
SE0303180D0 (sv) Novel compounds
AR051026A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
AR058728A1 (es) Derivados de aril-isoxazol-4-il-imidazo[1,5-a]piridina, metodo de preparacion,medicamentos que los contienen y usos en el tratamiento de trastornos cognitivos.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal